[
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "The CYP2C19*17 allele may be associated with increased bleeding risks.",
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Clopidogrel: label-recommended dosage and administration",
        "drugrecommendation_short": "Clopidogrel: label-recommended dosage and administration",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351554",
        "implications": {
            "CYP2C19": "Increased platelet inhibition; decreased residual platelet aggregation"
        },
        "lookupkey": {
            "CYP2C19": "Ultrarapid Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Ultrarapid Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": "The CYP2C19*17 allele may be associated with increased bleeding risks.",
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Clopidogrel: label-recommended dosage and administration",
        "drugrecommendation_short": "Clopidogrel: label-recommended dosage and administration",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351555",
        "implications": {
            "CYP2C19": "Increased platelet inhibition; decreased residual platelet aggregation"
        },
        "lookupkey": {
            "CYP2C19": "Rapid Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Rapid Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Clopidogrel: label-recommended dosage and administration",
        "drugrecommendation_short": "Clopidogrel: label-recommended dosage and administration",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351556",
        "implications": {
            "CYP2C19": "Normal platelet inhibition; normal residual platelet aggregation"
        },
        "lookupkey": {
            "CYP2C19": "Normal Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Normal Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "drugrecommendation_short": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351557",
        "implications": {
            "CYP2C19": "Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "lookupkey": {
            "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Moderate",
        "comments": null,
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "drugrecommendation_short": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351558",
        "implications": {
            "CYP2C19": "Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "lookupkey": {
            "CYP2C19": "Intermediate Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Intermediate Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "drugrecommendation_short": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351559",
        "implications": {
            "CYP2C19": "Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "lookupkey": {
            "CYP2C19": "Likely Poor Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Likely Poor Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "Strong",
        "comments": null,
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "drugrecommendation_short": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351560",
        "implications": {
            "CYP2C19": "Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer"
        },
        "population": "general",
        "version": "1"
    },
    {
        "activityscore": {
            "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "classification": "No Recommendation.",
        "comments": null,
        "drug": {
            "name": "clopidogrel"
        },
        "drugid": "RxNorm:32968",
        "drugrecommendation": "No Recommendation.",
        "drugrecommendation_short": "No Recommendation.",
        "guideline": {
            "name": "CYP2C19 and Clopidogrel"
        },
        "guidelineid": "100411",
        "id": "1351561",
        "implications": {
            "CYP2C19": "n/a"
        },
        "lookupkey": {
            "CYP2C19": "Indeterminate"
        },
        "phenotypes": {
            "CYP2C19": "Indeterminate"
        },
        "population": "general",
        "version": "1"
    }
]